Sale of US FDA-Approved Pharma Assets to PMC Group
Trumont provides advisory services to Isochem SAS in the insolvency restructuring and asset sale of three US-FDA approved API and advanced intermediates facilities to PMC Group (Mount Laurel, NJ)
MOUNT LAUREL, New Jersey (December 5, 2017) -- PMC Group France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of the pharma business of Isochem SAS of France. This is a fully integrated business comprised of research, product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates and active pharma ingredients (APIs) for major pharmaceutical companies worldwide to serve the needs of Oncology, Cardiovascular, Infectious, Gastro-Intestinal, Neurology and rare diseases. These facilities with combined footprint of over 40 acres are located at three sites -- Gennevilliers, Pithiviers, and Vert-Le-Petit -- within a 60 miles radius of Paris. The facilities, which are all cGMP US-FDA audited plants for manufacturing pharmaceutical products, will henceforth forth be called PMC Isochem SAS and the latter with 230+ employees will operate as a wholly owned subsidiary of PMC Group France. The Isochem pharma assets had sales of EUR 54.5 million in the last fiscal year (to Dec. 31, 2016).
December 5, 2017